

1  
2 **ACTION (physical aCTiviTY In minOrity womEN with asthma) intervention**  
3

4 **Principal Investigator:**

5 [Sharmilee Nyenhuis, MD FAAAAI  
6 Assistant Professor Medicine  
7 University of Illinois at Chicago,  
8 840 S. Wood St. MC 719 Chicago, IL 60612  
9 312-413-1655, [snyenhui@uic.edu](mailto:snyenhui@uic.edu)]

10  
11 **Co-Investigators:**

12 Lisa Sharp, PhD

13 Associate Professor of Pharmacy  
14 University of Illinois at Chicago  
15 1747 West Roosevelt Road MC 275 Chicago, IL 60608  
16 312-355-3569, [sharp1@uic.edu](mailto:sharp1@uic.edu)  
17

18  
19 David Marquez, PhD

20 Associate Professor of Kinesiology  
21 University of Illinois at Chicago  
22 632 Applied Health Sciences Bldg., 1919 W. Taylor Street, Chicago, IL 60612  
23 312- 996-1209, [marquezd@uic.edu](mailto:marquezd@uic.edu)

24 JoEllen Wilbur, PhD APN

25 Associate Dean of Research, Professor of Nursing  
26 Rush University, College of Nursing  
27 600 S. Paulina St. Suite 1062A Chicago, IL 60612  
28 312-942-8947 [joellen\\_wilbur@rush.edu](mailto:joellen_wilbur@rush.edu)  
29

30 Spyros Kitsiou, PhD

31 Assistant Professor of Biomedical and Health Information Sciences  
32 632 Applied Health Sciences Bldg., MC 530 1919 W. Taylor Street, Chicago, IL 60612  
33 University of Illinois at Chicago  
34 312-355-3519, [skitsiou@uic.edu](mailto:skitsiou@uic.edu)  
35  
36  
37

38  
39  
40  
41  
  
42  
  
43  
44  
  
45  
  
46  
  
47  
  
48  
49

**Study Location(s):**

1. University Illinois at Chicago
  2. Chicago Park District
- 541 N Fairbanks Ct, Chicago, IL 60611

**Sponsor:** [National Heart, Lung and Blood Institute, Central Society of Clinical and Translational Research]

**Version:** [20]

**Date:** [April 23<sup>rd</sup>, 2021]

50 [The Table of Contents can be updated by going to the “References” menu in the  
51 toolbar, then “Update Table”.]

	Page
52	
53	
54	Table of Contents .....3
55	List of Abbreviations .....4
56	<b>1.0 Project Summary/Abstract .....5</b>
57	<b>2.0 Background/Scientific Rationale .....6</b>
58	<b>3.0 Objectives/Aims .....6</b>
59	<b>4.0 Eligibility .....8</b>
60	<b>4.1 Inclusion Criteria .....8</b>
61	<b>4.2 Exclusion Criteria .....8</b>
62	<b>4.3 Excluded or Vulnerable Populations .....9</b>
63	<b>5.0 Subject Enrollment .....10</b>
64	<b>6.0 Study Design and Procedures .....11</b>
65	<b>7.0 Expected Risks/Benefits .....23</b>
66	<b>8.0 Data Collection and Management Procedures .....24</b>
67	<b>9.0 Data Analysis/Quality Control .....25</b>
68	<b>10.0 Data and Safety Monitoring .....26</b>
69	<b>11.0 Statistical Considerations .....28</b>
70	<b>12.0 Regulatory Requirements .....28</b>
71	<b>12.1 Informed Consent .....28</b>
72	<b>12.2 Subject Confidentiality .....30</b>
73	<b>12.3 Unanticipated Problems .....30</b>
74	<b>13.0 References .....31</b>
75	Appendices .....32
76	
77	

## LIST OF ABBREVIATIONS

78		
79		
80	AA	African American
81	ACQ	Asthma Control Questionnaire
82	ACTION	physicAl aCtiviTy In minOrity womeN with asthma
83	DSMP	Data and Safety Monitoring Plan
84	EHR	Electronic Health Record
85	HIPAA	Health Insurance Portability and Accountability Act
86	IRB	Institutional Review Board
87	ISWT	Incremental Shuttle Walk Test
88	NIH	National Institutes of Health
89	OPRS	Office for the Protection of Research Subjects
90	PA	Physical Activity
91	PHI	Protected Health Information
92	PI	Principal Investigator
93	SAE	Serious Adverse Event
94		
95		

96 **1.0 Project Summary/Abstract**

97 Physical inactivity in asthma is associated with worse asthma outcomes and African  
98 American women are disproportionately impacted by both physical inactivity and  
99 asthma. Research aimed at addressing the unique asthma-related and cultural-specific  
100 barriers to physical activity in this vulnerable population of women is needed. The  
101 proposed study will modify a validated community-based walking intervention specific to  
102 the needs of sedentary African American women with asthma and evaluate the impact  
103 of the intervention on physical activity and asthma specific indicators to reduce the  
104 burden of asthma in sedentary African American women.  
105

## 106 2.0 Background/Scientific Rationale

107 Asthma is a highly prevalent chronic disease that disproportionately impacts African  
108 American (AA) women. AA women have poorer asthma-related quality of life and higher  
109 rates of asthma exacerbations, healthcare utilization and mortality compared to  
110 Caucasian women. Further, AA women are less physically active than any other  
111 subgroup of adults, which may help explain the asthma health disparities, found  
112 between AA and Caucasian women. Physical inactivity among individuals with asthma  
113 is associated with poor asthma control and respiratory function, greater health care  
114 utilization, and poorer quality of life. Given the connection between poor asthma  
115 outcomes and physical inactivity, addressing physical activity (PA) among sedentary AA  
116 women with asthma is imperative. Physical activity demonstrated improvement in  
117 asthma outcomes specifically asthma control, quality of life and healthcare utilization.  
118 Despite these benefits, fewer than 25% of AA women with asthma engage in regular  
119 physical activity. The **ACTION intervention: physicAl aCtivity In minOrity womeN  
120 with asthma** is a 8-month community-based walking intervention refined to be  
121 applicable for sedentary AA women with asthma.  
122

123 This project will obtain and incorporate stakeholder input on the barriers and facilitators  
124 to engaging in physical activity with asthma to a validated community-based walking  
125 intervention. Once modified, we will pre-pilot the intervention in 10 participants, refine  
126 further in response to participant feedback and then test the feasibility, acceptability and  
127 estimate the efficacy of the intervention in a randomized controlled pilot of 80  
128 participants within a pragmatic community setting convenient for sedentary AA women.  
129

## 131 3.0 Objectives/Aims

132 The proposed study has 5 aims involving a total of 135 sedentary AA women with  
133 asthma.  
134

135 **NOTE:** Aims 1 and 2 have been IRB approved and completed. Only data analysis of  
136 these 2 aims are still occurring. At this time, I am requesting approval for Aim 3 which  
137 entails pilot testing the intervention to assess the feasibility, acceptability and to  
138 estimate the efficacy of the ACTION intervention.  
139

140 **Aim 1:** Use stakeholder input to modify a validated walking intervention for sedentary  
141 AA women with asthma.


142 **Aim 1a:** Conduct focus groups in 30 sedentary AA women with asthma to assess PA  
143 barriers and facilitators.  
144

145 **Aim 1b:** Adapt a validated walking intervention that addresses the barriers and  
146 facilitators to PA unique to sedentary AA women with asthma obtained from Aim 1A.  
147  
148

149 **Aim 2:** Pre-pilot test ACTION (physicAl aCtivity In minOrity womeN with asthma)  
150 intervention in up to 10 sedentary AA women with asthma to refine the recruitment  
151

152 materials, approach, design, and intervention content.


Figure 1. Study Design for ACTION Pre-pilot



153  
154  
155  
157  
158  
159  
160

**Aim 3:** Pilot test ACTION intervention in 80 sedentary AA women with asthma to assess acceptability, feasibility and estimate the efficacy to appropriately power a subsequent efficacy trial.

Figure 2. Study Design for Aim 3 (ACTION RCT Pilot)



161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176

**Aim 4:** Modify and refine the video component of the intervention to address the asthma-specific barriers to walking in AA women with asthma.

**Aim 4a:** Conduct a focus group with an Asthma Advisory Council (AAC) that includes up to 15 AA women with asthma, to assess the appropriateness of the proposed asthma content, language and setting used in the videos.

**Aim 4b:** Adapt the video component of the intervention using an iterative approach to include appropriate asthma content, language and setting.

**Aim 5:** Assess the acceptability of the revised videos by the AAC using a mixed methods approach (qualitative and quantitative data).

**Aim 6:** Disseminate research findings and next steps to women that participated in Aims 1-3.

177 **4.0 Eligibility/Inclusion and Exclusion Criteria (for Aims 1, 2 and 3)**

178

179 Participants will be recruited from the UI Health System.

180

- 181 • **Eligibility considerations:** We chose to focus on sedentary AA women with
- 182 sub-optimally controlled persistent asthma (based on ACQ score  $\geq 1.5$ /Appendix
- 183 1 OR ACT score  $\geq 20$ /Appendix 2) as long-term goal is to see an effect change in
- 184 asthma control. During our focus groups, we will discuss if there is a preferred
- 185 age range and will refine the intervention accordingly. Focus group participants
- 186 did not express a preferred age range so a diverse age range of participants will
- 187 be recruited to ensure representation from a diverse population of AA women
- 188 with asthma. Women that have completed participation in Aims 1, 2, or 3 of this
- 189 study will be able to participate in Aims 4 and 5 of the study.

190

191

192 **4.1 Inclusion Criteria**

193 **4.1.a. Aims 1 and 2:**

194

195

196

197

198

199

200

- Self-identify as female and black or AA
- Age 18-70
- Self-report  $< 150$  min/week of moderate intensity PA
- Sub-optimally controlled persistent asthma based on Asthma Control Questionnaire (ACQ  $\geq 1.5$ ) OR Asthma Control Test (ACT  $< 20$ )
- Willing to enroll and provide written-informed consent

201 **4.1.b. Aim 3**

202

203

204

205

206

207

208

209

- Self-identify as female and black or AA
- Age 18-70
- Sub-optimally controlled persistent asthma based on Asthma Control Test (ACT  $< 20$ )
- Willing to enroll and provide written-informed consent
- Have a smartphone or tablet device
- Willing to be randomly assigned to treatment or control group

210 **4.1.c. Aims 4 and 5**

211

212

213

214

215

216 **4.2 Exclusion Criteria:**

217

217 **4.2.a. Aims 1 and 2**

218

219

220

221

- Plans to move from Chicago during the study period
- Unable to ambulate without human assistance
- History of significant mental illness (e.g. uncontrolled bipolar disorder, psychoses)



- 222 • Currently pregnant, planning to become pregnant over the next 3 months
- 223 • Diagnosis of COPD (emphysema or chronic bronchitis) suggested by patient
- 224 report of doctor diagnosis or smoking history (>20 pack years)
- 225 • Family/household member of another study participant or staff member
- 226 • Inability to speak, read or understand English;
- 227 • Investigator discretion for safety or protocol adherence reasons

228  
229

**4.2.b. Aim 3**

- 230 • Plans to relocate outside of the Chicagoland area during the study period.
- 231 • Unable to ambulate without human assistance (ie. use of a wheelchair, scooter)
- 232 • History of significant mental illness (e.g. uncontrolled bipolar disorder,
- 233 psychoses)
- 234 • Currently pregnant, planning to become pregnant over the next 3 months
- 235 • Diagnosis of COPD (emphysema or chronic bronchitis) suggested by patient
- 236 report of doctor diagnosis or smoking history (>20 pack years)
- 237 • Poorly controlled high blood pressure (BP >180/100 at baseline visit)
- 238 • Family/household member of another study participant or staff member
- 239 • Inability to speak, read or understand English;
- 240 • Investigator discretion for safety or protocol adherence reasons
- 241 • Participation in Aim 2 of this study

242

243 We will use the Exercise Assessment and Screening for You (EASY) questionnaire  
 244 (Appendix 3 to detect the presence of conditions that could preclude study participation.  
 245 Current physical activity (PA) screening guidelines from a consensus group from the  
 246 American Heart Association and the American College of Cardiology no longer  
 247 recommend routine stress testing for those initiating a PA program. The EASY  
 248 questionnaire has clear recommendations for when evaluation by a physician is needed  
 249 before beginning a PA program (e.g., when the individual reports new-onset shortness  
 250 of breath, pain, or dizziness that has not been previously evaluated by a health care  
 251 provider), and we will follow these recommendations.

252

253 If the EASY questionnaire recommends that a potential participant be evaluated by a  
 254 health care provider prior to starting a PA program, the potential participant will be  
 255 asked to contact their health care provider or we will obtain permission from the  
 256 participant to contact their UI Health provider. We will send their UI Health provider a  
 257 secure message describing the study and it's procedures and the results of their  
 258 patient's EASY questionnaire. We will request a response regarding permission of entry  
 259 into the study. Permission from their health care provider will be required prior to  
 260 participation in any study activities.

261

262 **Exclusion criteria for spirometry procedure only done at 1 data collection visit**  
 263 **(Visit 1) in the pre-pilot and 3 data collection visits in the pilot: chest or abdominal**  
 264 **surgery in previous 6 weeks, detached retina or eye surgery in previous month.**

265 **NOTE: This will be assessed at data collection visits only. If participant meets**  
266 **these exclusion criteria, then spirometry will not be performed.**  
267

#### 268 **4.2.c. Aims 4 and 5**

- 269 • Plans to move from Chicago during the study period
- 270 • Diagnosis of COPD (emphysema or chronic bronchitis) suggested by patient  
271 report of doctor diagnosis or smoking history (>20 pack years)
- 272 • Inability to speak, read or understand English;
- 273 • Investigator discretion for safety or protocol adherence reasons

### 274 **4.3 Excluded or Vulnerable Populations**

275 **EXCLUSION OF MINORS** Although asthma is a disease that affects both children and  
276 adults the focus of this proposal is to specifically modify and pilot test an existing  
277 physical activity intervention in sedentary African American women with asthma.  
278 Children are intentionally being excluded, as currently there is insufficient data available  
279 in African American adults with asthma to judge the potential risk of this intervention in  
280 children.  
281

282 **INCLUSION OF WOMEN AND MINORITIES** The focus population for this study is  
283 sedentary African-American (AA) women with asthma. All participants included in the  
284 study will self-identify themselves as female and black or AA. This study population was  
285 chosen as AA women are disproportionately impacted by physical inactivity and asthma  
286 compared to Caucasian men and women and AA men. In particular, AA women have  
287 the highest rates of asthma-related mortality and asthma-related health-care utilization.  
288 Physical inactivity in asthma is particularly relevant because it is associated with worse  
289 asthma outcomes, specifically, poor asthma control and respiratory function, greater  
290 health care utilization, and poorer quality of life. Research aimed at addressing physical  
291 inactivity and asthma control in this vulnerable population of women is needed.  
292

### 293 **5.0 Subject Enrollment**

294 Potential participants will be identified using 3 methods: 1) Using a validated electronic  
295 health record (EHR) algorithm (Appendix 4) that identifies asthma patients with a high  
296 sensitivity and specificity (99% and 96%, respectively)[1]; 2) From healthcare providers  
297 in internal medicine, pulmonary and allergy/asthma clinics at UI Health; 3) From women  
298 that were screened in Aims 1-3 and provided permission to contact them for future  
299 studies.  
300

#### 301 **5.1 Asthma algorithm identification**

302 The EHR asthma algorithm will be performed by Dr. William Galanter, co-investigator.  
303 We have experience using this EHR algorithm at UIC for an ongoing asthma study,  
304 CAPriCORN (ChairB Protocol #14111301). A HIPAA waiver will be obtained for this  
305 research to allow us to gather information about potential study participants and contact  
306 the potential participants. Two methods of recruitment will be used: in-person and  
307

308 mailings. In-person recruitment will occur in the UI Health outpatient clinics. We will  
309 approach potential participants who are already coming to UI Health for an appointment.  
310 In a given week, we will verify ahead of time what potential participants are coming to  
311 the clinics that have also been identified through the EHR asthma algorithm. A research  
312 assistant(s) will come to the outpatient clinic for the potential participant's appointment,  
313 obtain verbal agreement from potential participant's doctor/provider to approach the  
314 potential participant, then approach the potential participant and give a brief introduction  
315 about the study and ask screening questions to assess eligibility. If eligible and  
316 interested, the study will be introduced to the potential participant and if interested  
317 scheduled for a focus group session (Aim 1) or the first study visit (baseline interview  
318 and initial data collection) which will take place in the Clinical Research Center at UIC  
319 (Aim 2 and 3). Alternatively, the recruiter and potential participant can set up another  
320 day or a phone call to assess eligibility, describe the study and/or schedule the initial  
321 visit. All patients approached must be identified by our EHR asthma algorithm.

322  
323 For mail recruitment, letters along with a response card will be sent to women identified  
324 by the algorithm. Within 1 week, telephone contact will be made unless the response  
325 card is returned indicating that they are not interested. Participants will be called up to 5  
326 times to recruit a potential subject via telephone. If the potential participant doesn't  
327 answer the phone call, a recruitment voicemail will be left up to 5 times. A brief  
328 telephone screen will assess eligibility, describe the study and interest in participation. If  
329 interested and eligible, patients will be scheduled for a focus group (Aim 1) or the first  
330 study visit (baseline interview and initial data collection) which will take place in the  
331 Clinical Research Center at UIC (Aim 2 and 3). Written informed consent will be  
332 obtained in person in a private area prior to starting the focus group session (Aim 1) or  
333 the baseline interview and data collection (Aim 2 and 3) for all participants.

## 334 335 336 **5.2 Healthcare provider identification**

337 In our second selection strategy, a research assistant (RA) will work closely with  
338 healthcare providers who see a lot of patients with asthma in their clinics (Internal  
339 Medicine, Pulmonary and Allergy/Asthma).

- 340 1. The RA will go to Internal Medicine, Pulmonary and/or Allergy/Asthma clinics and  
341 introduce themselves to the healthcare providers and provide them a brief  
342 synopsis of the research study (See study synopsis V1 11\_20\_17).
- 343 2. The RA will ask healthcare providers for potential participant's that have  
344 physician diagnosed asthma and obtain verbal agreement from the healthcare  
345 provider to approach the potential participant.
- 346 3. The RA will approach the patient and give a brief introduction about the study  
347 and ask screening questions to assess eligibility using the in-person screening  
348 script.
- 349 4. If the patient is eligible and interested, the study will be introduced to them and if  
350 interested scheduled for the first study visit (baseline interview and initial data  
351 collection) which will take place in the Clinical Research Center at UIC (Aim 3).

- 352 5. Alternatively, the potential participant may be given a flyer about the study or the  
353 recruiter and potential participant can set up another time to assess eligibility,  
354 describe the study and/or schedule the initial visit by phone or in-person.  
355

### 356 **5.3 Women screened for Aims 1-3**

- 357 1. Women that were screened for Aims 1-3 AND provided permission to contact  
358 them for future phases of this research will be contacted via preferred method of  
359 contact (phone/text/email). The RA will contact the participant and give a brief  
360 introduction about the study and ask screening questions to assess eligibility  
361 using the telephone screening script.  
362 2. If the patient is eligible and interested, the study will be introduced to them and if  
363 interested the RA will obtain times that are ideal for the participant for the focus  
364 group.  
365  
366

### 367 **5.4 Eligibility Screening**

368 If a participant does not meet eligibility criteria during screening, this will be indicated on  
369 an encrypted data sheet so that participants are not approached multiple times. The de-  
370 identified data collected from the screen failures will be entered into REDCap by key  
371 research personnel.  
372

373 The principal investigator will separate clinical responsibilities and influence from the  
374 recruitment process by having key research personnel perform eligibility screening and  
375 informed consent of potential participants. The physicians will be informed of the study  
376 and its' objectives at a faculty meeting and will be asked if they have any concerns  
377 regard their patients' participation.  
378

## 379 **6.0 Study Design and Procedures**

### 381 **Aim 1 (focus groups)**

382 We will randomly select 160 women with the goal of recruiting a random sample of 30  
383 women. We will use the recruitment method described above in Section 5.0.

384 Participants will be selected to ensure representation of a range of asthma severity and  
385 current age. The sample size is determined by the theoretical saturation or the point  
386 when no new ideas relevant to the question are obtained, which is generally 15[2].

387 However, a minimum of 20 is recommended for illness studies[3]. This study includes  
388 30 participants in groups of 6-10 for focus groups. If redundancy is not noted in the  
389 focus group discussion, additional participants will be included until saturation is  
390 reached.  
391

392 To ensure that the focus groups are responsive to the participants and unexpected  
393 themes that might emerge, data analysis will begin after the first focus group data are  
394 entered and continue throughout the focus group phase.  
395

- 396 Study Procedures for Aim 1:
- 397 1. Complete eligibility screening.
  - 398 2. Securing informed consent.
  - 399 3. Complete a brief demographic form. (Appendix 5)
  - 400 4. Attend one 2 hour focus group and provide perspective on issues such as
  - 401 physical activity and asthma. Provide feedback and recommendations on
  - 402 recruitment materials, content structure, and approach of ACTION intervention.

403

404 Drs. Nyenhuis and Sharp will moderate all focus groups using an interview guide

405 (Appendix 6) with semi-structured open-ended questions. The interview guide will be

406 pre-tested for clarity, comprehension, and sensitivity and will provide sufficient flexibility

407 to pursue unanticipated facets of topics that emerge in focus group discussions[4].

408

409 Each group will last approximately 2 hours and be audio-recorded and subsequently

410 transcribed by a member of the research team. Patients will complete written consent,

411 receive \$50 (gift card or cash) and light snacks/refreshments.

412

413 The focus groups will take place in a private space in one of 3 places:

- 414 1. Chicago Park District location that is in close approximation to where the
  - 415 participants live. The exact location will be determined with the help of the
  - 416 Chicago Park District liaison and will take into account safety of the participants
  - 417 and the location of where participants live.
  - 418 2. The University of Illinois at Chicago Institute of Health Research and Policy
  - 419 3. For participants that are interested but unable to any other the other scheduled
  - 420 visits, we will arrange for an individual interview at UI Health.
- 421

422 The Chicago Park District will only host focus groups and no Chicago Park District staff

423 are involved in the research as recruiters or to collect data.

424

425 Key research personnel will send a reminder text and/or call the patient (based on

426 patient preference) 24-48 hours prior to the focus group stating “UIC group will meet at

427 X time and X place.”

428

429 **Aim 2 (Pre-pilot)**

430 We will select up to 10 women using the recruitment method described above in Section

431 5.0. Potential participants and participants for Aim 1 will be eligible to participate in Aim

432 2 if they expressed an interest to participate in future phases of the study. Participants

433 will be selected to ensure representation of a range of asthma severity and current age.

434

435 Study Procedures for Aim 2 (Appendix 7- Table of study procedures):

436 **Screening:**

437 Potential participants will undergo eligibility screening either in-person (UI Health  
438 patients who are already coming to UI Health for an appointment) or over the telephone.  
439 If eligible and interested in participating in the study, they will be scheduled for their first  
440 study visit (Visit 1).

441  
442 **Visit 1: (See appendix 8 for measures)**

443 At visit 1 the following procedures will take place at the Clinical Research Center at UIC:

- 444 1. Secure informed consent.
- 445 2. Complete a brief demographic form.
- 446 3. Spirometry performed according to American Thoracic Society guidelines.  
447 Participants will be asked to wear nose clips and to take a deep breath in and  
448 blow their breath out as fast as they can into the spirometer. We will perform  
449 repeated measurements (3 to 8 times) to ensure accuracy of results.
- 450 4. Height and Weight
- 451 5. Incremental Shuttle Walk Test (ISWT) performed according to American  
452 Thoracic Society guidelines
- 453 6. Physical activity questionnaires
- 454 7. Asthma Control Questionnaire (ACQ)
- 455 8. Asthma-related quality of life questionnaire (AQLQ)
- 456 9. PROMIS measures (Global Health, social roles satisfaction, mood, sleep)
- 457 10. Asthma Knowledge and Self-efficacy questionnaire (KASE-AQ)
- 458 11. Dyspnea questionnaire
- 459 12. Active Where Questionnaire
- 460 13. Self-efficacy for walking scale
- 461 14. Social support for exercise survey
- 462 15. Outcome expectation scale for exercise
- 463 16. Epworth sleepiness scale-pending permission
- 464 17. Sleep Apnea Scale of the Sleep Disorders Questionnaire- pending permission
- 465 18. Pittsburgh Sleep Quality Instrument
- 466 19. Schedule Visit 2 with participant

467  
468 Key research personnel will obtain consent in a private room in the Clinical  
469 Research Center. After consent is obtained, the other study procedures will be  
470 completed. This visit will last approximately 2 hours and upon completion the  
471 participant will receive \$25 cash or gift card. Patients will be offered light  
472 snacks/refreshments at this visit.

473  
474 Participants will then be provided the following equipment at Visit 1:

475 Actigraph accelerometer: This will be given to participants to assess their baseline  
476 and post-intervention daily number of steps. Participants will be verbally instructed  
477 to wear it attached to their waist at all times while awake. The Actigraph  
478 accelerometer (Figure 3) is a research accelerometer (1.8 inches at its largest  
479 dimension, weight 19 grams). This will be returned at Visit 2. The data from the  
480 accelerometers will be downloaded to Actigraph software (ActiLife 6.13.3) when the  
481 accelerometers are returned. Only study ID will be used in the actigraph software.  
482 No identifiable information will be maintained in the Actigraph software.  
483

484 Figure 3. Actigraph accelerometer



485  
486 **Visits 2-4 (1-2 weeks after each prior visit):**  
487 Visits 2-4 will take place at UI Health/UIC or a Chicago Park District (CPD) location that  
488 is in close approximation to where the participants live. The exact CPD location will be  
489 determined with the help of the Chicago Park District liaison and will take into account  
490 safety of the participants and the location of where participants live. The Chicago Park  
491 District will only provide space for these visits and no Chicago Park District staff are  
492 involved in the research as recruiters or to collect data.  
493

494 At visits 2-4 the following procedures will occur:

- 495 1. Collection of accelerometers (Visit 2 only) and Fitbit (Visit 4 only).
- 496 2. Attend a 2 hour group session at the Chicago Park District or at UI  
497 Health/UIC. At the group session, participants will receive basic asthma  
498 education, physical activity education and watch a video on how to get started  
499 to walk. Participants will be asked to share their experiences with asthma and  
500 physical activity.
- 501 3. Each participant will be given an individualized step-goal not to exceed 3000  
502 steps above their baseline calculated from accelerometer data. (Visit 2 and 3  
503 only)
- 504 4. Each participant will be given an ACTION participant manual (Visit 2 only).
- 505 5. Participants will be asked to complete a session evaluation form. (Appendix 9)
- 506 6. Summative evaluation (visit 4 only; Appendix 10)

507  
508

509 Key research personnel will send a reminder text, call and/or email (based on patient  
510 preference) up to 3 times the prior week to the group session stating “ACTION group  
511 will meet at X time and X place.”

512  
513 Reminder messages will also be sent via phone, text or email (based on participant  
514 preference) up to 3 times per week to help them attain their weekly step goal (See  
515 Appendix 11 for sample text messaging).

516  
517 An interventionist and/or Dr. Nyenhuis will attend the group sessions. Each group will  
518 last approximately 2 hours and be audio-recorded to assess for intervention fidelity. If a  
519 participant declines audio-recording the session, then the session will not be recorded.  
520 The PI or co-investigator may then observe a group session intermittently to assess for  
521 intervention fidelity. If the session is recorded, the PI will review portions of the session.  
522 The sessions will be deleted once the pre-pilot is complete. These audio recordings will  
523 not be transcribed. Patients will receive light snacks/refreshments at each session.

524  
525 Key research personnel will send a reminder text, email and/or call the patient (based  
526 on patient preference) 24-48 hours prior to each visit.

527  
528 Participants will then be provided the following equipment at Visit 2 and will be asked to  
529 return on Visit 4:

530 1) Fitbit® physical activity monitor: Participants will be verbally instructed to wear it on  
531 their wrist at all times while awake. The Fitbit (Figure 3.a) is a commercially-available  
532 physical activity monitor (0.83 inches wide, weight 0.8 ounces). The wristbands are  
533 adjustable and data from our focus groups revealed that participants would prefer a  
534 wrist-based than a waist-based physical activity monitor. Participants will be asked to  
535 download the fitbit app to their smartphone or tablet and asked to create an account.  
536 Participants will be referred to the Fitbit website for troubleshooting. This will allow for  
537 physical activity data transmission to the Fitbit study database which will not contain any  
538 identifiable information. A previous survey found that over 90% of our patients had a  
539 smartphone or tablet. If a participant is unable to or does not want to download the fitbit  
540 app then they will write their daily steps into a journal which they will bring to each study  
541 visit. Participants will not be responsible for the cost of the Fitbit if it is lost or stolen.

542



543 Figure 4. Fitbit physical activity monitor

544



545 Daily physical activity, heart rate and status of the Fitbit (e.g., battery) will be monitored  
546 in real time using a Fitbit study database. Only physical activity data (i.e., step counts,  
547 time worn using heart rate, minutes active, distance walked) of the participant will be  
548 kept in the Fitbit study database. This is necessary for recording of detailed physical  
549 activity data as the pedometers have limited data storage capacity. Only study ID will be  
550 used in the Fitbit study database. No identifiable information will be maintained in the  
551 Fitbit database.

552  
553 Participants will be given a \$25 gift card or cash after completion of study visit 4.  
554

### 555 **Aim 3 (Pilot)**

556 We will randomly select 800 women with the goal of recruiting a random sample of 80  
557 women. We will use the recruitment method described above in Section 5.0.

558 Participants will be selected to ensure representation of a range of asthma severity, BMI  
559 and current age. Potential participants for Aim 1 and 2 will be eligible to participate in  
560 Aim 3 if they did not participate in the focus groups or the pre-pilot but expressed an  
561 interest to participate in future phases of the study.

562  
563 Study Procedures for Aim 3 (Appendix 7- Table of study procedures):

#### 564 **Screening:**

565 Potential participants will undergo eligibility screening either in-person (UI Health  
566 patients who are already coming to UI Health for an appointment) or over the telephone.  
567 If eligible and interested in participating in the study, they will be scheduled for their first  
568 study visit (Visit 1).

### 569 570 **3 Data Collection Visits: Baseline (week 0/Visit 1), post adoption phase (week** 571 **24/Visit 7a/b) and post maintenance phase (week 36/Visit 9) in all participants** 572 **(See appendix 8 for measures)**

573 At the data collection visits, the following procedures will take place at the Clinical  
574 Research Center at UIC or Chicago Park District location:

- 575 1. Secure informed consent (1<sup>st</sup> visit only).
- 576 2. Complete a brief demographic form.
- 577 3. Spirometry performed according to American Thoracic Society guidelines.  
578 Participants will be asked to wear nose clips and to take a deep breath in and  
579 blow their breath out as fast as they can into the spirometer. We will perform  
580 repeated measurements (3 to 8 times) to ensure accuracy of results.
- 581 4. Height and Weight
- 582 5. Incremental Shuttle Walk Test (ISWT) performed according to American  
583 Thoracic Society guidelines
- 584 6. Physical activity questionnaires

- 585 7. Asthma Safety Measures  
586 8. Asthma Control Questionnaire (ACQ)  
587 9. Asthma-related quality of life questionnaire (AQLQ)  
588 10. Adult Asthma Adherence Questionnaire (AAAQ)  
589 11. PROMIS measures (Global Health, social roles satisfaction, mood, sleep)  
590 12. Active Where Questionnaire  
591 13. Self-efficacy for walking scale  
592 14. Social support for exercise survey  
593 15. Outcome expectation scale for exercise  
594 16. Sleep Apnea Scale of the Sleep Disorders Questionnaire  
595 17. Pittsburgh Sleep Quality Instrument  
596 18. Neighborhood safety and social cohesion questionnaire  
597 19. Study randomization (1<sup>st</sup> visit only)  
598 20. Schedule asthma and physical activity (PA) education session with participant  
599 (1<sup>st</sup> visit only)  
600

601 Key research personnel will obtain consent in a private room in the Clinical  
602 Research Center. After consent is obtained, the other study procedures will be  
603 completed.  
604

605 This visit will last approximately 2 hours and upon completion the participant will  
606 receive \$35 cash or gift card. Patients will be offered light snacks/refreshments  
607 at this visit and given a visit summary sheet with their blood pressure, heart rate,  
608 weight, height, oxygen level, date of next study visit and a copy of spirometry  
609 results if desired.  
610

611 Participants will then be provided the following equipment at these data collection  
612 visits:

613 Actigraph accelerometer: This will be given to participants to assess their baseline  
614 and post-intervention daily number of steps. Participants will be verbally instructed  
615 to wear it attached to their wrist at all times while awake. The Actigraph  
616 accelerometer (Figure 3) is a research accelerometer (1.8 inches at its largest  
617 dimension, weight 19 grams). This will be returned within 2 weeks of the data  
618 collection visit. The accelerometers can be returned either in person at the asthma  
619 and PA session, in a postage paid envelope or the participant and the research  
620 assistant will find a mutually agreeable place to pick up the accelerometer from the  
621 participant. The participant will not incur any charges if the accelerometer is lost or  
622 stolen. The data from the accelerometers will be downloaded to Actigraph software  
623 (ActiLife 6.13.3) when the accelerometers are returned. Only study ID will be used

624 in the actigraph software. No identifiable information will be maintained in the  
625 Actigraph software.

626  
627 Participants are typically asked to wear the accelerometer for 7 days (does not  
628 have to be consecutive). However, valid baseline measurement of activity can be  
629 obtained with an average of 10 hours per day for 4 days. This is the minimum  
630 amount of accelerometer data required to continue participation in the intervention.  
631 If the participant does not wear the accelerometer for sufficient time to provide valid  
632 baseline measure (ie. an average of 10 hours per day for 4 days), they will be  
633 offered a second opportunity to wear the accelerometer. If the participant declines  
634 or is unable to wear the accelerometer again within 3 weeks of returning the  
635 accelerometer, then the participant will be withdrawn from the study.

636  
637 **Enhanced Usual Care Group (home-based walking program):** The comparison  
638 group will be instructed to achieve a static goal of 10,000 steps per day. The US  
639 Surgeon General recommends accumulating 30 minutes of activity most days of the  
640 week. Assuming that an individual gets 6,000 steps from their other daily activities, 30  
641 minutes of walking can help one achieve a goal of approximately 10,000 steps per day.

642  
643 Participants will be given a Fitbit Charge HR® which will measure their daily steps (see  
644 more detail below under visit 2). In order to attention-match for interactions with study  
645 staff, participants will attend an asthma education and physical activity training session.  
646 Newsletters with walking tips for AA women and asthma education topics will be sent  
647 twice during the intervention phases to participants in this group. Participants will come  
648 to the Clinical Research Center for data collection at weeks 24 (Visit 7b) and 36 (Visit 9)  
649 described in more detail below.

650  
651 **Asthma and physical activity (PA) education session for all participants (1-6**  
652 **weeks after baseline data collection visit)**

653 The asthma and PA education session will take place at UI Health/UIC or a Chicago  
654 Park District (CPD) location that is in close approximation to where the participants live.  
655 The exact CPD location will be determined with the help of the Chicago Park District  
656 liaison and will take into account safety of the participants and the location of where  
657 participants live. The Chicago Park District will only provide space for these visits and  
658 no Chicago Park District staff are involved in the research as recruiters or to collect  
659 data. Two separate asthma/PA education sessions will take place, one for enhanced  
660 usual care group and one for those randomized into the intervention group.

661  
662 At the asthma/PA education session the following procedures will occur:

663 1. Collection of accelerometers for those that have not already returned it.

- 664 2. Attend a 2 hour group session at the Chicago Park District or at UI  
665 Health/UIC. At the group session, participants will receive didactic asthma  
666 education and information on how to engage in physical activity with their  
667 asthma.  
668 3. Participants will be asked to complete a session evaluation form. (Appendix 9)  
669 4. Participants will be given \$5 cash to assist with travel expenses incurred for  
670 the visit.

671  
672 Key research personnel will send a reminder text, call and/or email (based on patient  
673 preference) up to 3 times the prior week to the group session stating “Asthma and  
674 physical activity session will meet at X time and X place.”  
675

676 An asthma educator, a research assistant(s) and/or Dr. Nyenhuis will attend the  
677 education session. Each education session will last approximately 2 hours. Patients will  
678 receive light snacks/refreshments at each session.  
679

680 For missed sessions, make-up sessions will be offered (in-person or by video).  
681 Continuation in the program will be decided by the PI on a case by case basis.  
682 Participants will be strongly encouraged to make up missed sessions prior to the next  
683 scheduled group session (intervention group) or data collection visit (enhanced usual  
684 care group).  
685

686 Participants will be given the following equipment at the asthma/PA education session:  
687 1) Fitbit® physical activity monitor: Participants will be verbally instructed to wear it on  
688 their wrist at all times while awake. The Fitbit (Figure 4) is a commercially-available  
689 physical activity monitor (0.83 inches wide, weight 0.8 ounces). The wristbands are  
690 adjustable and data from our focus groups revealed that participants would prefer a  
691 wrist-based than a waist-based physical activity monitor. Participants will be asked to  
692 download the fitbit app to their smartphone or tablet and asked to create an account.  
693 Participants will be referred to the Fitbit website for troubleshooting. This will allow for  
694 physical activity data transmission to the Fitbit study database which will not contain any  
695 identifiable information. If a participant is unable to or does not want to download the  
696 fitbit app then they will write their daily steps into a journal which they will bring to each  
697 study visit. Participants will not be responsible for the cost of the Fitbit if it is lost or  
698 stolen.  
699

700 Daily physical activity, heart rate and status of the Fitbit (e.g., battery) will be monitored  
701 in real time using a Fitbit study database. Only physical activity data (i.e., step counts,  
702 time worn using heart rate, minutes active, distance walked) of the participant will be  
703 kept in the Fitbit study database. This is necessary for recording of detailed physical

704 activity data as the pedometers have limited data storage capacity. Only study ID will be  
705 used in the Fitbit study database. No identifiable information will be maintained in the  
706 Fitbit database.

707  
708 **Group sessions (Intervention group only):** Women randomized into the intervention  
709 group will also attend group sessions in 2 phases: Adoption and Maintenance (See  
710 Figure 2).

711  
712 **Adoption phase (5 sessions every 4 weeks)**

713 The group session will take place at UI Health/UIC or a Chicago Park District (CPD)  
714 location that is in close approximation to where the participants live. The exact CPD  
715 location will be determined with the help of the Chicago Park District liaison and will take  
716 into account safety of the participants and the location of where participants live. The  
717 Chicago Park District will only provide space for these visits and no Chicago Park  
718 District staff are involved in the research as recruiters, interventionists, asthma  
719 educators or to collect data.

720  
721 At each group session the following will occur:

- 722 1. Women will attend a 2 hour group session at the Chicago Park District or at  
723 UI Health/UIC. At the group session, participants will continue to receive  
724 asthma education (short videos and/or didactic session), watch a video on  
725 how to get started to walk and what barriers they may face. Participants will  
726 be asked to share their experiences engaging in physical activity with asthma.
- 727 2. Participant will be given an individualized step-goal not to exceed 3000 steps  
728 above their baseline calculated from accelerometer data over the entire  
729 course of the study.
- 730 3. Each participant will be given an ACTION participant manual (1<sup>st</sup> group  
731 session only).
- 732 4. Participants will be encouraged to walk during the group session for up to 15  
733 minutes. The interventionist and Chicago Park District liaison will identify safe  
734 locations for the women to walk at the group session site. Women will be able  
735 to walk at their own pace and stop at anytime. If the participant does not want  
736 to participate in the walking portion of the group visit they may opt-out by  
737 verbally telling the interventionist that they do not want to participate.
- 738 5. Participants will be asked to complete a session evaluation form. (Appendix  
739 9).
- 740 6. Participants will be given \$5 cash to assist with travel expenses incurred for  
741 each group visit.

742

743 At the last group session in the adoptive phase, the following procedures will occur and  
744 the participant will receive \$35 cash or gift card for this visit only:

745 :

- 746 1. Spirometry performed according to American Thoracic Society guidelines.  
747 Participants will be asked to wear nose clips and to take a deep breath in and  
748 blow their breath out as fast as they can into the spirometer. We will perform  
749 repeated measurements (3 to 8 times) to ensure accuracy of results.
- 750 2. Weight
- 751 3. Incremental Shuttle Walk Test (ISWT) performed according to American  
752 Thoracic Society guidelines
- 753 4. Accelerometer distribution
- 754 5. Summative evaluation (visit 7 only; Appendix 10)

755

756 If a participant is not able to attend this session, we will contact the patient to scheduled  
757 an in person data collection visit at UI Health/UIC where the above procedures (#1-3)  
758 will be completed.

759

760 During or after Visit 7a is complete, participants will complete REDCap paper surveys (  
761 in person) or will be sent a link (email or text) to complete the following REDCap  
762 surveys electronically:

- 763 1. Physical activity questionnaires
- 764 2. Asthma Safety Measures
- 765 3. Asthma Control Questionnaire (ACQ)
- 766 4. Asthma-related quality of life questionnaire (AQLQ)
- 767 5. Adult Asthma Adherence Questionnaire (AAAQ)
- 768 6. PROMIS measures (Global Health, social roles satisfaction, mood, sleep)
- 769 7. Active Where Questionnaire
- 770 8. Self-efficacy for walking scale
- 771 9. Social support for exercise survey
- 772 10. Outcome expectation scale for exercise
- 773 11. Sleep Apnea Scale of the Sleep Disorders Questionnaire
- 774 12. Pittsburgh Sleep Quality Instrument

775 Key research personnel will send a reminder text, call and/or email (based on patient  
776 preference) up to 3 times the prior week to the group session stating “ACTION Asthma  
777 group will meet at X time and X place.”

778

779 Reminder messages will also be sent via phone, text or email (based on participant  
780 preference) up to 3 times per week to help them attain their weekly step goal (See  
781 Appendix 11 for sample text messaging).

782

783 An interventionist and/or Dr. Nyenhuis will attend the group sessions. Each group will  
784 last approximately 2 hours and may be audio-recorded to assess for intervention fidelity.  
785 If a participant declines audio-recording the session, then the session will not be  
786 recorded. The PI or co-investigator may then observe a group session intermittently to  
787 assess for intervention fidelity. If the session is recorded, the PI will review portions of  
788 the session. The sessions will be deleted once the pilot is complete. These audio  
789 recordings will not be transcribed. Patients will receive light snacks/refreshments at  
790 each session.

791

792 If any of the group visits 3-7 are missed, the woman is asked to arrive 15 minutes early  
793 for the next meeting to receive an update. Her report will be emailed/phones/texted to her  
794 depending on her preference.

795

796 If a woman has missed several group visits and we have been unable to contact her, we  
797 will mail her a letter indicating to call us.

798

799 **Visit 7b: 24 week data collection (Enhanced Usual Care only)**

800 At Visit 7b the following procedures will take place at the Clinical Research Center at  
801 UIC:

- 802 1. Spirometry performed according to American Thoracic Society guidelines.  
803 Participants will be asked to wear nose clips and to take a deep breath in and  
804 blow their breath out as fast as they can into the spirometer. We will perform  
805 repeated measurements (3 to 8 times) to ensure accuracy of results.
- 806 2. Weight
- 807 3. Incremental Shuttle Walk Test (ISWT) performed according to American  
808 Thoracic Society guidelines
- 809 4. Accelerometer distribution
- 810 5. Physical activity questionnaires
- 811 6. Asthma Safety Measures
- 812 7. Asthma Control Questionnaire (ACQ)
- 813 8. Asthma-related quality of life questionnaire (AQLQ)
- 814 9. Adult Asthma Adherence Questionnaire (AAAQ)
- 815 10. PROMIS measures (Global Health, social roles satisfaction, mood, sleep)
- 816 11. Active Where Questionnaire
- 817 12. Self-efficacy for walking scale
- 818 13. Social support for exercise survey
- 819 14. Outcome expectation scale for exercise
- 820 15. Sleep Apnea Scale of the Sleep Disorders Questionnaire
- 821 16. Pittsburgh Sleep Quality Instrument

822

823 This visit will last approximately 2 hours and upon completion the participant will receive  
824 \$35 cash or gift card.

825

826 Participants will be given a postage paid envelope and be asked to mail the  
827 accelerometer back to study team after wearing it for 1 week. Reminder  
828 calls/texts/emails will be sent if we have not received the accelerometer within 2 weeks  
829 of completion of visit 7. If needed, a central location for drop-off of the accelerometer  
830 may be arranged with the participant.

831

832 **Maintenance Phase:** During the maintenance phase, participants will continue to  
833 receive reminder text messages to help them attain their weekly step goal no more than  
834 once a week.

835

836 **Visit 8: Post-maintenance booster session and data collection (12 weeks after**  
837 **Visit 7) Booster session will only be for intervention group.**

838

839 At visit 8 booster session the following procedures will occur:

- 840 1. Attend a 2 hour group session at the Chicago Park District or at UI  
841 Health/UIC. At the group session, participants will review successes attained  
842 and barriers, lapses, and relapses encountered.
- 843 2. Participants will be asked to complete a session evaluation form. (Appendix 9).
- 844 3. Participants will be given \$5 cash to assist with travel expenses incurred for  
845 the group visit.

846

847 An interventionist and/or Dr. Nyenhuis will attend the group session. The group will last  
848 approximately 2 hours and may be digitally recorded to assess for intervention fidelity. If  
849 a participant declines audio-recording the session, then the session will not be  
850 recorded. The PI or co-investigator may then observe a group session intermittently to  
851 assess for intervention fidelity. If the session is recorded, the PI will review portions of  
852 the session. The session will be deleted once the pilot is complete. These audio  
853 recordings will not be transcribed. Patients will receive light snacks/refreshments at the  
854 session.

855

856 **Post-maintenance data collection (all participants)**

857 The following procedures will take place at the Chicago Park District (intervention  
858 group) or Clinical Research Center at UIC (enhanced usual care):

- 859 1. Spirometry performed according to American Thoracic Society guidelines.  
860 Participants will be asked to wear nose clips and to take a deep breath in and  
861 blow their breath out as fast as they can into the spirometer. We will perform  
862 repeated measurements (3 to 8 times) to ensure accuracy of results.



- 863 2. Weight  
864 3. Incremental Shuttle Walk Test (ISWT) performed according to American  
865 Thoracic Society guidelines  
866 4. Distribution of accelerometer  
867  
868

869 The following questionnaires will be completed by REDCap survey:

- 870 1. Physical activity questionnaires  
871 2. Asthma Safety Measures  
872 3. Asthma Control Questionnaire (ACQ)  
873 4. Asthma-related quality of life questionnaire (AQLQ)  
874 5. Adult Asthma Adherence Questionnaire (AAAQ)  
875 6. PROMIS measures (Global Health, social roles satisfaction, mood, sleep)  
876 7. Active Where Questionnaire  
877 8. Self-efficacy for walking scale  
878 9. Social support for exercise survey  
879 10. Outcome expectation scale for exercise  
880 11. Sleep Apnea Scale of the Sleep Disorders Questionnaire  
881 12. Pittsburgh Sleep Quality Instrument  
882

883 This visit will last approximately 2 hours and upon completion the participant will  
884 receive \$35 cash or gift card. Patients will be offered light snacks/refreshments  
885 at this visit.  
886

887 Participants will be given a postage paid envelope and be asked to mail the  
888 accelerometer back to study team after wearing it for 1 week. Reminder  
889 calls/texts/emails will be sent if we have not received the accelerometer within 2 weeks  
890 of completion of visit 8. If needed, a central location for drop-off of the accelerometer  
891 may be arranged with the participant.  
892

### 893 **Aims 4 & 5 (Adapting Intervention Tools)**

894 We will recruit up to 15 AA women with asthma from our database of ~80 AA women  
895 with asthma that have given us permission to contact them for research studies. These  
896 women have already been identified as having asthma either through physician  
897 diagnosis and/or the use of a validated electronic health record (EHR) algorithm that  
898 identifies asthma patients with a high sensitivity and specificity (99% and 96%,  
899 respectively)[15, 16]. Potential participants will be contacted and asked screening  
900 questions to ensure they are still in our target age range of 18-70 years. Participants will  
901 be selected to ensure representation of age ranges. The sample size is determined by  
902 the theoretical saturation or the point when no new ideas relevant to the question are

903 obtained, which is generally 15[17].

904

905 Study Procedures for Aims 4 and 5:

906 1. Complete eligibility screening.

907 2. Securing informed consent.

908 3. Complete a brief demographic form. (Appendix 5)

909 4. Attend three 90 minute focus groups and provide perspective on issues such  
910 as video content, video scene selection and final video product.

911

912 Drs. Nyenhuis and a nurse interventionist will moderate all focus groups using an  
913 interview guide (Appendix 12) with semi-structured open-ended questions. The  
914 interview guide will be pre-tested for clarity, comprehension, and sensitivity and will  
915 provide sufficient flexibility to pursue unanticipated facets of topics that emerge in focus  
916 group discussions[4].

917

918 Each group will last approximately 90 minutes and be audio-recorded and subsequently  
919 transcribed. If one of the focus group members decline to be audio-recorded the  
920 session will not be audio-recorded and only field notes will be collected. Patients will  
921 complete written consent (1<sup>st</sup> session only), receive \$50 (cash) and light  
922 snacks/refreshments at each focus group.

923

924 The focus groups will take place in a private space at the University of Illinois at  
925 Chicago.

926

927 Key research personnel will send a reminder text and/or call the patient (based on  
928 patient preference) 24-48 hours prior to the focus group stating “ACTION asthma group  
929 will meet at X time and X place.”

930

### 931 **Aim 6 (Dissemination of study findings to study participants)**

932 We will disseminate our study findings and next steps to study participants by way of a  
933 newsletter. Using feedback from the CCTS Community Advisory Board we developed  
934 three newsletters to be disseminated to our study participants. The newsletters focus on  
935 thanking our participants, study findings, next steps and educational content related to  
936 physical activity and/or asthma. The newsletter will be sent on a monthly basis for 3  
937 months and will be disseminated by email, text or mail based on the preferred  
938 communication each participant indicated in the study. A pdf of the newsletters will be  
939 also available on Dr. Nyenhuis’ Department of Medicine Research Page.

940

## 941 **7.0 Expected Risks/Benefits**

942

943 The research involves minimal risk:

944  
945  
946  
947  
948  
949  
950  
951  
952  
953  
954  
955  
956  
957  
958  
959  
960  
961  
962  
963  
964  
965  
966  
967  
968  
969  
970  
971  
972  
973  
974

1. There is a chance that answering questions about their health may cause participants to become upset or distressed. If this should happen during a focus group or group session, the participant may take a break from the group or leave the group entirely.
2. Questionnaires: given that some questions ask personal information; it is possible that participants will be uncomfortable answering them. Participants will be explained they do not have to answer any question they are uncomfortable with.
3. There is also a chance for loss of privacy and loss of confidentiality in the unlikely event that unauthorized persons should see study data. Many protections will be taken to decrease the chances that this happens.
4. Spirometry (lung function test): risks associated with spirometry are minimal for most people. Because the test involves rapid and forced breathing, some people may experience temporary (lasting up to a few minutes) shortness of breath, lightheadedness and minor chest soreness. In rare cases, the participant may hyperventilate and become dizzy during spirometric testing. Any participant who feels faint should be guided onto the chair with her head down towards the knees, and encouraged to breathe slowly and deeply until she recovers. If the participant fails to recover normal breathing, faints, or reports feeling ill, the research assistant will summon the CRC nurse manager and physician immediately. The physician should always be consulted if there is any question regarding the participant's safety status during the exam.
5. Risk of pulmonary event: subjects will be asked to increase their daily physical activity and will perform up to 15 minutes of walking during the intervention group sessions, so there is the possibility of a pulmonary complication, such as an increase in respiratory symptoms (shortness of breath, cough, wheezing). We will minimize this risk by careful participant selection. Previous studies have shown the safety of increasing physical activity in sub-optimally controlled persistent asthma (Ma J et al. Ann Am Thorac Soc. 2015; 12(1): 1–11.)

975 Participants may have direct personal benefits from participating in the pre-pilot and  
976 pilot, as they will receive asthma education and learn how to best exercise with asthma.  
977 Further, participants may enjoy talking with other people about their experiences with  
978 asthma and physical activity. The participant's involvement will offer important  
979 information that will help refine and test the feasibility and acceptability of a physical  
980 activity program to improve the life of women with asthma.

## 981 **8.0 Data Collection and Management Procedures**

982 Data collected during screening of participants will be entered into REDCap by key  
983 research personnel. For subjects that are interested in participating in future studies or  
984 future phases of the study, their contact information will be entered and secured in a  
985

986 REDCap database. The asthma algorithm output (raw data) will only be seen by Dr.  
987 Galanter. The data from the algorithm that is needed to contact the potential participants  
988 (name, address, phone number, date of birth and medical record number) will be kept  
989 within the hospital intranet, behind the clinical hospital firewall that is password  
990 protected and will be accessed only by the PI and selected key research personnel.  
991

992 The data from the focus groups (Aims 1, 4 and 5) will be in the form of audio recordings  
993 with no use of names. Drs. Nyenhuis and Sharp will review focus group transcriptions to  
994 identify recurring themes especially those focused on barriers and enablers to  
995 PA/walking and video adaptation and video acceptability. We will explore the distribution  
996 across the groups by key variables such as asthma severity and age. In this manner,  
997 analysis will consider the context of the responses including characteristics of the  
998 participants[5]. Information drawn from focus groups will not be shared with group  
999 participants. The audio of the focus groups will be destroyed after transcription. The  
1000 transcript data will be destroyed immediately before the research has been closed via a  
1001 Final Report.  
1002

1003 The data from the pre-pilot and pilot will be in the form of a demographics form, surveys,  
1004 Fitbit data (step counts, time worn using heart rate, minutes active, distance walked),  
1005 accelerometer data and spirometry results. Each form, survey or report will have the  
1006 participant's study ID only. The participant's height and weight will be directly entered  
1007 into REDCap by key research personnel. After each study visit, key research personnel  
1008 will ensure that the data is entered into the REDCap database. Paper copies of the  
1009 demographics form, paper surveys (if used), and spirometry results will be kept in a  
1010 locked cabinet or drawer separate from the study ID code. The paper copies will be  
1011 destroyed immediately before the research has been closed via a Final Report.  
1012 Electronic REDCap surveys will also be used and once complete will be automatically  
1013 transferred into REDCap.

1014  
1015 Other clinical data (ie. laboratory data, pulmonary function tests, sleep tests) will be  
1016 obtained from the participant's UI Health electronic medical record (EMR). This data will  
1017 be entered into REDCap and will have the participant's study ID only. This data will be  
1018 used to assess the feasibility and preliminary efficacy of the PA intervention in different  
1019 phenotypes of asthma.

1020 Actual data and information connecting a study participant's name and study identifying  
1021 number is kept in a locked file drawer in the PI's office. The coding system will be kept  
1022 in a locked cabinet or drawer separate from the actual data. Research investigators  
1023 performing the statistical analyses data will not have access to information that can  
1024 connect up the actual identity of a study participant and their data. All workstations  
1025 require the use of a password in order to gain access. When leaving a workstation  
1026 unattended, the user must log-out or lock their computer. Users are required to use

1027 screen savers that will be activated after ten minutes of inactivity and are password  
1028 protected.

1029

## 1030 **9.0 Data Analysis/Quality Control**

1031

### 1032 Aim 1: Focus Group Data Analysis/Quality Control

1033 To ensure that the focus groups are responsive to the participants and unexpected  
1034 themes that might emerge, data analysis will begin after the first focus group data are  
1035 entered and continue throughout the focus group phase. Drs. Nyenhuis and Sharp will  
1036 review focus group transcriptions to identify recurring themes especially those focused  
1037 on barriers and enablers to PA/walking and explore the distribution across the groups  
1038 by key variables such as asthma severity and age. In this manner, analysis will  
1039 consider the context of the responses including characteristics of the participants[5].  
1040 The list of themes will serve as the data for the intervention refinement, which will occur  
1041 as part of Aim 1b.

1042

1043 The intent of Aim 1b is to integrate the barriers and facilitators to PA unique to  
1044 sedentary AA women with asthma obtained from Aim 1a to adapt a validated walking  
1045 intervention. A multi-disciplinary asthma advisory team, consisting of kinesiologist- Dr.  
1046 Marquez, exercise-induced asthma specialist- Dr. Moy, PA in women specialist- Dr.  
1047 Wilbur and behavioral scientist- Dr. Sharp will meet to review the results and generate  
1048 independent suggestions related to safe and effective PA with asthma and asthma-  
1049 related barriers and enablers to PA. This team will also address modifications specific to  
1050 asthma such as: 1) identification of asthma triggers (exercise, pollens, cold-air); 2)  
1051 adequate warm-up prior to physical activity; 3) medication pre-treatment prior to  
1052 physical activity; 4) adequate cool-down after physical activity; 5) use of breathing  
1053 exercises. The group will review and rank order all suggestions for intervention  
1054 modifications. Final decisions will be determined by the Asthma Advisory Team: Drs.  
1055 Marquez, Sharp, Moy, Wilbur and Nyenhuis. The resulting intervention will be used in  
1056 Aim 2 (Pre-pilot).

1057

1058 Aim 2: Pre-pilot ACTION Intervention: The qualitative data collected during pre-pilot will  
1059 include but not be limited to, measures of time to administer and recruitment,  
1060 exploration of variance on measures (ceiling and floor effects), formative evaluations  
1061 from group sessions and issues with data collection and entry. The asthma advisory  
1062 team will review all aspects of the pre-pilot and recommend refinement of the content,  
1063 logistics, or process of the intervention. No further modifications will be made and we  
1064 will proceed to obtaining IRB approval for the final aim of the study (Aim 3).

1065

1066 Aim 3: Pilot ACTION Intervention: The qualitative data collected during pilot will include  
1067 but not be limited to, measures of time to administer and recruitment, exploration of  
1068 variance on measures (ceiling and floor effects), formative evaluations from group  
1069 sessions and issues with data collection and entry. The quantitative data collected will  
1070 include lung function, height/weight, body mass index, shuttle walk test time,  
1071 surveys/questionnaires, EMR data (laboratory data, pulmonary function tests and sleep

1072 tests). This data will be stored in REDCap and will be monitored periodically by the  
1073 study statistician.

1074  
1075 **Aim 4: Adapting Intervention tools:** Audio recordings of the focus groups will be  
1076 transcribed and compared to field notes collected during the focus group meetings. An  
1077 initial list of codes will be used based upon the facilitator guides used in the focus  
1078 groups. The meeting transcript will be coded independently by the PI and a research  
1079 assistant and will meet several times to group the codes into categories and add  
1080 definitions for each code so that the coding process is consistent. The list of themes will  
1081 serve as the data for the video refinement. Data analysis strategies for demographic  
1082 data will use descriptive statistics.

1083  
1084 A multi-disciplinary research team, consisting of an asthma specialist- Dr. Nyenhuis, PA  
1085 in women specialist- Dr. Wilbur (mentor on Dr. Nyenhuis' K award) and behavioral  
1086 scientist- Dr. Sharp (primary mentor on Dr. Nyenhuis' K award) will meet to review the  
1087 results from the initial focus group meeting. The group will review and rank order all  
1088 suggestions for video modifications. Final decisions will be determined by Drs.  
1089 Nyenhuis, Wilbur and Sharp. The resulting suggestions of asthma content, setting and  
1090 language will be used to develop the script for the videos working with an experienced  
1091 videographer and filming will begin.

1092  
1093 The relevant raw video footage will be presented at the second focus group meeting.  
1094 The women will be asked to provide feedback (written and oral) on the selection of  
1095 video scenes from the raw video footage clips that are relevant to the added asthma  
1096 video content. The written feedback includes a scoring sheet for each video. Each video  
1097 will be scored two times. Once for relevance of the asthma content to engaging in  
1098 physical activity and second for the usefulness in stimulating group discussion. Each  
1099 score will be on a 5-point scale from not relevant to very relevant or not useful to very  
1100 useful. Field notes will be taken during the meeting and the session will be audio  
1101 recorded and subsequently transcribed. The field notes and meeting transcript will be  
1102 reviewed by the PI and research assistant independently. The mean ratings of video  
1103 scenes' relevance and usefulness will be calculated. The mean scores for each video  
1104 will be used as rationale for replacing unacceptable scores (<3) The suggestions for  
1105 scene inclusion will be reviewed and finalized with the multi-disciplinary research team  
1106 and reviewed with the videographer. The resulting video will be used in Aim 5.

1107  
1108 **Aim 5:** During the third focus group the women will review the six edited videos and  
1109 provide feedback on the acceptability of the videos. Acceptability will be measured for  
1110 each video using a 4-item summative evaluation using a 5-point scale, which will  
1111 address overall satisfaction, content and language used in each video. Open-ended  
1112 questions asked by the moderators will capture participants' thoughts on what their likes  
1113 and dislikes about the videos. This session will be audiotaped and transcribed.

1114  
1115 The PI and RA will review the transcribed discussions and the mean scores from each  
1116 question on the questionnaire will be calculated.

1117

1118 **Aim 6:** No data will be collected in this aim.

1119

## 1120 **10.0 Data and Safety Monitoring**

1121 During this study, data and safety-monitoring will occur to to ensure the safety of study  
1122 participants and the validity of data in compliance with the National Institutes of Health  
1123 (NIH) requirement of Data and Safety Monitoring for Clinical Trials. The Data and  
1124 Safety Monitoring for the proposed project has three goals: (1) to insure the safety of  
1125 the participants; (2) to produce high quality research while considering both risks and  
1126 benefits.

1127

1128 This section outlines essential elements of the Data and Safety Monitoring (DSM) for  
1129 this study.

1130 a) **Monitoring the Progress of the Trial and Safety of Participants:** This study poses  
1131 minimal risk to the participants, as it involves getting the participant's opinions on  
1132 the use of behavioral counseling and low-impact exercise, walking. Drs. Sharp and  
1133 Nyenhuis will perform local monitoring of the progress of the trial and the safety of  
1134 participants.

1135

1136 b) **Plans for Assuring Compliance with Requirements Regarding the Reporting of**  
1137 **Adverse Events (AE):**  
1138 Participants will be given the study office phone number (24-hour coverage) to  
1139 contact study staff and/or investigators to report adverse events. All adverse events  
1140 will be reported to the IRB and study sponsor (NIH).

1141

1142 Information about adverse events experienced by study participants will be  
1143 monitored by the following means:

- 1144 • Report given by study participants to study staff, either in person or by telephone.
- 1145 • Report given to study staff by study participants' family or friends, either in person  
1146 or by telephone.
- 1147 • Report by the participant's physician or other health care provider involved in her  
1148 care.
- 1149 • Report from a hospital or other healthcare facility where the study participant(s) is  
1150 being treated for the serious adverse event.
- 1151 • Other persons who may have knowledge of such a serious adverse event.

1152

1153 Upon receiving a report of a serious adverse event:

- 1154 • The study staff will contact Dr. Nyenhuis (at 312-572-9179) or Dr. Sharp (312-355-  
1155 3569) as soon as possible.
- 1156 • Drs. Nyenhuis or Sharp will complete the Adverse Event Report and submit the  
1157 completed form to the Human Subjects Committee of the University of Illinois at  
1158 Chicago and the NIH within 24 hours of learning of the adverse event.
- 1159 • A copy of the adverse event form will be kept in the study file.

1160

1161 Drs. Nyenhuis and Sharp will assess recruitment flow, attendance, retention rates,  
1162 and AE summaries weekly during team meetings. Data from the focus groups will  
1163 be recorded and transcribed by a member of the research team for review by Drs.  
1164 Nyenhuis and Sharp. Procedures will be reviewed to insure that the data collected  
1165 are collected in a manner consistent with the confidentiality of the participants  
1166 involved.

1167

#### 1168 Monitoring the Progress of the Trial and the Safety of Participants.

1169 Overall, the study poses minimal risk to participants. A safety office will be named and  
1170 reports will be tendered every quarter to monitor progress and problems. The report  
1171 provided to the safety office will including periodic assessments of data quality and  
1172 timeliness, participant recruitment, accrual and retention, participant risk versus benefit,  
1173 participant complaints (if any), adverse events, and other factors that can affect study  
1174 outcomes. Summaries of enrollment, attendance, and withdrawals will be reviewed. If  
1175 we are not meeting our recruitment/retention goals we may consider the following  
1176 retention methods that have been used by other co-investigators in this patient  
1177 population such as: 1) Sending notes of appreciation, birthday cards or holiday cards; 2)  
1178 Small tokens of appreciation. If a participant is unable to provide acceptable  
1179 accelerometer data (as described above) or is withdrawn from the study, a final letter  
1180 will be mailed to the participant (See *Letter to participants that are withdrawn*). The  
1181 research team will report any problems expressed by participants to the PI either in  
1182 person or by telephone within 24 hours of the problem. She will then pass this on to the  
1183 IRB and other appropriate oversight bodies.

1184

#### 1185 Reporting Adverse Events.

1186 The safety officer will be immediately notified of any adverse events. All adverse  
1187 events will be reported to the Institutional Review Board (IRB).

1188

### 1189 **11.0 Statistical Considerations**

#### 1190 Aim 1: Focus Groups

1191 We will randomly select 160 women with the goal of recruiting a random sample of 30  
1192 women. Participants will be selected to ensure representation of a range of variables  
1193 including asthma severity, current age and menopausal status. The sample size is  
1194 determined by the theoretical saturation or the point when no new ideas relevant to the  
1195 question are obtained, which is generally 15<sup>53</sup>. However, a minimum of 20 is  
1196 recommended for illness studies<sup>54</sup>. This study includes 30 participants in groups of 6-10  
1197 for focus groups. If redundancy is not noted in the focus group discussion, additional  
1198 participants will be included until saturation is reached.

1199 Qualitative analysis will occur after the focus groups. We will review focus group  
1200 transcriptions to identify recurring themes especially those focused on barriers and  
1201 enablers to PA/walking and explore the distribution across the groups by key variables  
1202 such as asthma severity and age.



1203 Aim 2: Pre-pilot ACTION Intervention  
1204 One hundred women will be screened and up to 10 women will be selected to  
1205 participate in the pre-pilot. Participants will be selected to ensure representation of a  
1206 range of variables including asthma severity, current age and menopausal status. As  
1207 the goal of this portion of the study is to test run the intervention and inform further  
1208 refinement of the study methods no specific sample size calculations were performed.

1209  
1210 Aim 3: Pilot ACTION intervention  
1211 Eight hundred women will be screened and up to 80 women will be selected to  
1212 participate in the pilot. Participants will be selected to ensure representation of a range  
1213 of variables including asthma severity, current age and BMI. Participants will be  
1214 randomized using REDCap randomization program. As the goal of this portion of the  
1215 study is to test the feasibility, acceptability and estimate the efficacy of the modified  
1216 intervention thus no specific sample size calculations were performed.

1217  
1218 Aims 4 and 5: Adapting Intervention tools

1219 We will recruit up to 15 AA women with asthma from our database of ~80 AA women  
1220 with asthma that have given us permission to contact them for research studies. These  
1221 women have already been identified as having asthma either through physician  
1222 diagnosis and/or the use of a validated electronic health record (EHR) algorithm that  
1223 identifies asthma patients with a high sensitivity and specificity (99% and 96%,  
1224 respectively)[15, 16]. Potential participants will be contacted and asked screening  
1225 questions to ensure they are still in our target age range of 18-70 years. Participants will  
1226 be selected to ensure representation of age ranges. The sample size is determined by  
1227 the theoretical saturation or the point when no new ideas relevant to the question are  
1228 obtained, which is generally 15[17].

1229  
1230 Qualitative analysis will occur after the focus groups. We will review focus group  
1231 transcriptions to identify recurring themes especially those focused on video adaptation  
1232 and acceptability of the final product.

1233  
1234 Aim 6: Dissemination of study findings

1235 As no data is collected there will be no statistical analysis performed.

1236

## 1237 **12.0 Regulatory Requirements**

### 1238 **12.1 Informed Consent**

1239 As Aims 1-3 of this research involves no greater than minimal risk, we will obtain  
1240 eligibility and interest in participation over the phone or in person. All participants that  
1241 attend the focus group will provide written informed consent will be obtained prior to

1242 starting the focus group. All participants involved in Aims 2 and 3 of the intervention will  
1243 provide written informed consent prior to any study procedures taking place.

1244

1245 Informed consent will be obtained by key research personnel that have completed  
1246 training in human subjects research and obtaining informed consent.

1247

1248 We request a HIPAA Preparatory to Research, a waiver of informed consent for the  
1249 identification of potential participants in the recruitment phase of research.

1250

1251 This request is based on the following criteria that we will follow:

1252

1253 a. Use is sought solely to review protected health information as necessary to  
1254 perform the asthma algorithm in the UI Health EHR. prepare a research protocol  
1255 or for similar purposes preparatory to research (in this case identify participants  
1256 for recruitment);

1257

1258 b. No protected health information is to be removed from the covered entity by the  
1259 researcher in the course of the review and PHI will not be retained long term if  
1260 patient decide not to participate; and

1261

1262 c. The protected health information for which use or access is sought is necessary  
1263 for the research purposes.

1264

1265 The following criteria for the waiver of informed consent for the identification of potential  
1266 participants in the recruitment phase of the research will be met:

1267

1268 a. The recruitment phase of the research involves no more than minimal risk to the  
1269 participants;

1270 b. The waiver of informed consent for the identification of potential participants in the  
1271 recruitment phase of the research will not adversely affect the rights and welfare  
1272 of the participants;

1273 c. The recruitment phase of the research could not practicably be carried out without  
1274 the waiver of informed consent for the identification of potential participants in the  
1275 recruitment phase of the research; and

1276 d. If appropriate, the participants will be provided with additional pertinent  
1277 information after the recruitment phase of the research.

1278

1279 A waiver of documentation and an alteration of consent is requested for the eligibility  
1280 screening portion of the study.

1281           **12.2 Subject Confidentiality**

1282    Each participant will be given information about the purpose of the study and will  
1283    participate only after having signed the informed consent. Confidentiality will be  
1284    maintained by keeping research records in locked file drawers and all data will be  
1285    maintained on a secured network maintained in the Department of Medicine. We will  
1286    use identification numbers to insure confidentiality of the data files. Once collected, an  
1287    individual's data will not be available to anyone other than an authorized person on the  
1288    proposed project.

1289  
1290    Participants will receive a thorough introduction to the study preparing them for the  
1291    nature of the questions that will be asked in the focus group. Such preparation often  
1292    decreases the risk for becoming unduly distressed. If a participant does become  
1293    distressed, study staff will be trained to respond in a supportive, empathic way and to  
1294    give the participant the opportunity to take a break.

1295  
1296    Formal training on data and participant safety is provided to all research staff involved in  
1297    the data collection process. All staff and students involved in our research studies sign  
1298    a confidentiality agreement stating that they are aware that any data they come in  
1299    contact with is strictly confidential and is not to be discussed outside of the research  
1300    project. They also complete the University of Illinois at Chicago online training on  
1301    Human Subjects Protection (101) and the HIPAA Privacy Act.

1302

1303           **12.3 Unanticipated Problems**

1304    Unanticipated problems involving risks to participants or others (including adverse  
1305    events), will be reported to the UIC IRB and study sponsor (NIH) in a timely manner.

1306

1307 **13.0 References**

1308

1309 1. Pacheco, J.A., et al., *A highly specific algorithm for identifying asthma cases and*  
1310 *controls for genome-wide association studies*. AMIA Annu Symp Proc, 2009.

1311 **2009**: p. 497-501.

1312 2. Kvale, S., *Inter Views: An introduction to qualitative research interviewing*. 1996,  
1313 Thousand Oaks, CA: Sage.

1314 3. Conrad, P., *The experience of illness: Recent and new directions*, in *The*  
1315 *experience and management of chronic illness*, C.P. Roth JA, Editor. 1987, JAI  
1316 Press: Greenwich, CT.

1317 4. Charmaz, K., *Constructing grounded theory: A practical guide through qualitative*  
1318 *analysis*. 2006, London: Sage.

1319 5. S, F., *User's Manual for ATLAS.ti 5.0*. 2004, Scientific Software Development:  
1320 Berlin.

1321

1322

1323

## APPENDICES

*Appendix 1: Asthma Control Questionnaire (ACQ)*

*Appendix 2: Asthma Control Test (ACT)*

*Appendix 3: EASY Questionnaire*

*Appendix 4: Asthma Algorithm*

*Appendix 5: Basic Demographics Information*

*Appendix 6: Focus Group Guide/Questions*

*Appendix 7: Table of study procedures (pre-pilot 7a and pilot 7b)*

*Appendix 8: Survey measures*

*Appendix 9: Evaluation of group session*

*Appendix 10: Summative evaluation of intervention*

*Appendix 11: Text message content*

*Appendix 12: Focus group guide for adapting intervention tools*

*Appendix 13: Video Acceptability measure*

*Appendix 14: Sample dissemination newsletters*

*Appendix 15: Cover letter/email to accompany dissemination newsletter*

### Other documents

*Blank Output from Asthma Algorithm V1*

*Sample CRF for REDCAP V1*

*Link to videos used in group sessions:*

<https://www.rushu.rush.edu/womens-walking-program>

*Link to Asthma Education content: American Lung Association Asthma Basics*

<http://www.lung.org/lung-health-and-diseases/lung-disease-lookup/asthma/asthma-education-advocacy/asthma-basics.html>

*Sample participant walking program manual*

*Permission to contact health care provider*

*Email to UI Health provider for medical clearance*

*Participant letter for missed visits*

*Participant letter if withdrawn*

### Recruitment Documents

*Patient Letter*

#1-Focus Groups

#2-Pre-pilot intervention

#3- Pilot intervention

#4- Adapting tools- Focus Groups

Return Postcard

*Eligibility Script*

#1-Focus Groups: Phone and in-person

#2-Pre-pilot intervention: Phone and in-person

#3-Pilot intervention: Phone and In-person

#4- Adapting tools- Focus Groups: Phone and in-person

*Eligibility Screening Form*

#1-Focus Groups

#2-Pre-pilot intervention

#3- Pilot intervention

#4- Adapting tools- Focus Groups

*Informed Consent Document*

#1-Focus Groups

#2-Pre-pilot intervention

#3- Pilot intervention

#4- Adapting tools- Focus Groups